Observational study to compare antithrombin and thrombomodulin for disseminated intravascular coagulation

International Journal of Clinical Pharmacy

Volumn 37, Issue 1, 2015, Pages 139-147

  Murata, Atsuhiko ^a   Okamoto, Kohji ^b   Mayumi, Toshihiko ^c   Muramatsu, Keiji ^a   Matsuda, Shinya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Yahata Municipal Hospital   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Antithrombin; Database; Disseminated intravascular coagulation; Healthcare costs; Length of stay; Mortality; Thrombomodulin

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; DRUG THERAPY; THBD PROTEIN, HUMAN; THROMBOMODULIN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DIAGNOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG THERAPY; FACTUAL DATABASE; FEMALE; HOSPITALIZATION COST; HUMAN; INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTITHROMBIN III; DATABASES, FACTUAL; DIAGNOSIS; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG THERAPY; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MORTALITY; THERAPEUTIC USE; THROMBOMODULIN; TRENDS;

EID: 84964292230     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-014-0052-5     Document Type: Article

References (34)

1. Bick RL. Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis, and management: guidelines for care. Clin Appl Thromb Hemost. 2002;8(1):1–31.
2. Levi M, van der Poll T. Disseminated intravascular coagulation: a review for the internist. Intern Emerg Med. 2013;8(1):23–32.
3. Levi M, Schultz M, van der Poll T. Disseminated intravascular coagulation in infectious disease. Semin Thromb Hemost. 2010;36(4):367–77.
4. Nakagawa M, Tsuji H. Current trends in the diagnosis of disseminated intravascular coagulation in Japan: findings of questionnaire survey. Rinsho Ketsueki. 1999;40(5):362–4.
5. Gogos CA, Lekkou A, Papageorgiou O, Siagris D, Skoutelis A, Bassaris HP. Clinical prognostic markers in patients with severe sepsis: a prospective analysis of 139 consecutive cases. J Infect. 2003;47(4):300–6.
6. Cartin-Ceba R, Kojicic M, Li G, Kor DJ, Poulose J, Herasevich V, et al. Epidemiology of critical care syndromes, organ failures, and life-support interventions in a suburban US community. Chest. 2011;140(6):1447–55.
7. Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010;125(1):6–11.
8. Nishiyama T, Matsukawa T, Hanaoka K. Is protease inhibitor a choice for the treatment of pre-or mild disseminated intravascular coagulation? Crit Care Med. 2000;28(5):1419–22.
9. Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis. 2006;17(7):521–6.
10. Iba T, Saito D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res. 2012;130(3):e129–33.
11. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost. 2014;12(9):1470–9.
12. Shirahata A, Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, et al. Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation. Eur J Pediatr. 2014;173(3):303–11.
13. Ogawa Y, Yamakawa K, Ogura H, Kiguchi T, Mohri T, Nakamori Y, et al. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg. 2012;72(5):1150–7.
14. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5(1):31–41.
15. Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41(9):2069–79.
16. Murata A, Matsuda S. Association between ambulance distance to hospitals and mortality from acute diseases in Japan: national database analysis. J Public Health Manag Pract. 2013;19(5):E23–8.
17. Murata A, Matsuda S, Kuwabara K, Ichimiya Y, Matsuda Y, Kubo T, et al. Association between hospital volume and clinical outcomes of elderly patients with acute biliary diseases: a national administrative database analysis. Geriatr Gerontol Int. 2013;13(3):731–40.
18. Murata A, Okamoto K, Muramatsu K, Kubo T, Fujino Y, Matsuda S. Effects of additional laparoscopic cholecystectomy on outcomes of laparoscopic gastrectomy in patients with gastric cancer based on a national administrative database. J Surg Res. 2014;186(1):157–63.
19. Murata A, Muramatsu K, Ichimiya Y, Kubo T, Fujino Y, Matsuda S. Endoscopic submucosal dissection for gastric cancer in elderly Japanese patients: an observational study of financial costs of treatment based on a national administrative database. J Dig Dis. 2014;15(2):62–70.
20. Murata A, Okamoto K, Muramatsu K, Matsuda S. Endoscopic submucosal dissection for gastric cancer: the influence of hospital volume on complications and length of stay. Surg Endosc. 2014;28(4):1298–306.
21. Fukuda T, Yasunaga H, Horiguchi H, Ohe K, Fushimi K, Matsubara T, et al. Health care costs related to out-of-hospital cardiopulmonary arrest in Japan. Resuscitation. 2013;84(7):964–9.
22. Ministry of Health, Welfare and Labor of Japan. Stat. Chuikyo. 26.3.26 http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000041708.pdf. Accessed 8 Nov 2014
23. Murata A, Okamoto K, Muramastu K, Matsuda S. Time trend of medical economic outcomes of endoscopic submucosal dissection for gastric cancer in Japan: a national database analysis. Gastric Cancer. 2014;17(2):294–301.
24. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228.
25. Murata A, Okamoto K, Mayumi T, Muramatsu K, Matsuda S. The recent time trend of outcomes of disseminated intravascular coagulation in Japan: an observational study based on a national administrative database. J Thromb Thrombolysis. 2014;38(3):364–71.
26. Kato T, Sakai T, Kato M, Hagihara M, Hasegawa T, Matsuura K, et al. Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thromb J. 2013;11(1):3.
27. Yamakawa K, Fujimi S, Mohri T, Matsuda H, Nakamori Y, Hirose T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care. 2011;15(3):R123.
28. Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T, et al. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med. 2013;39(4):644–52.
29. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 2006;34(2):285–92.
30. Sawamura A, Gando S, Hayakawa M, Hoshino H, Kubota N, Sugano M. Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness. Clin Appl Thromb Hemost. 2009;15(5):561–6.
31. Sakamoto Y, Inoue S, Iwamura T, Yamashita T, Nakashima A, Nishimura Y, et al. Studies on therapeutic effects and pathological features of an antithrombin preparation in septic disseminated intravascular coagulation patients. Yonsei Med J. 2013;54(3):686–9.
32. Okamoto K, Takada T, Strasberg SM, Solomkin JS, Pitt HA, Garden OJ, et al. TG13 management bundles for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20(1):55–9.
33. Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res. 2013;131(5):436–43.
34. Murata A, Matsuda S, Mayumi T, Yokoe M, Kuwabara K, Ichimiya Y, et al. A descriptive study evaluating the circumstances of medical treatment for acute pancreatitis before publication of the new JPN guidelines based on the Japanese administrative database associated with the Diagnosis Procedure Combination system. J Hepatobiliary Pancreat Sci. 2011;18(5):678–83.